A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study

Neuromuscular Disorders

Volumn 25, Issue 7, 2015, Pages 554-562

  Hashizume, Atsushi ^a   Katsuno, Masahisa ^a   Suzuki, Keisuke ^a   Banno, Haruhiko ^a,b   Suga, Noriaki ^a   Mano, Tomoo ^a   Araki, Amane ^a   Hijikata, Yasuhiro ^a   Grunseich, Christopher ^c   Kokkinis, Angela ^c   Hirakawa, Akihiro ^a   Watanabe, Hirohisa ^a   Yamamoto, Masahiko ^d   Fischbeck, Kenneth H ^c   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Functional rating scale; Motor neuron disease; Spinal and bulbar muscular atrophy; Validation

Indexed keywords

ADULT; AGED; ARTICLE; BULBAR MUSCULAR ATROPHY; CONTROLLED STUDY; CONVERGENT VALIDITY; CORRELATION COEFFICIENT; CRONBACH ALPHA COEFFICIENT; CROSS-SECTIONAL STUDY; DISCRIMINANT VALIDITY; DISEASE COURSE; DISEASE DURATION; EXTERNAL VALIDITY; HUMAN; INTERNAL CONSISTENCY; INTERRATER RELIABILITY; INTRARATER RELIABILITY; JAPANESE (PEOPLE); LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; RELIABILITY; SPINAL MUSCULAR ATROPHY; VALIDITY; FACTOR ANALYSIS; JAPAN; LANGUAGE; MALE; MIDDLE AGED; MUSCULAR DISORDERS, ATROPHIC; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; VALIDATION STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FACTOR ANALYSIS, STATISTICAL; HUMANS; JAPAN; LANGUAGE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUSCULAR DISORDERS, ATROPHIC; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 84930541640     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2015.03.008     Document Type: Article

References (37)

1. Kennedy W.R., Alter M., Sung J.H. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 1968, 18:671-680.
2. Sobue G., Hashizume Y., Mukai E., et al. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 1989, 112:209-232.
3. Katsuno M., Tanaka F., Adachi H., et al. Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog Neurobiol 2012, 99(3):246-256.
4. Sperfeld A.D., Karitzky J., Brummer D., et al. X-linked bulbospinal neuronopathy: Kennedy disease. Arch Neurol 2002, 59:1921-1926.
5. Atsuta N., Watanabe H., Ito M., et al. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 2006, 129:1446-1455.
6. Banno H., Katsuno M., Suzuki K., et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 2009, 65:140-150.
7. Katsuno M., Banno H., Suzuki K., et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:875-884.
8. Fernández-Rhodes L.E., Kokkinis A.D., White M.J., et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol 2011, 10:140-147.
9. Querin G., D'Ascenzo C., Peterle E., et al. Pilot trial of clenbuterol in spinal and bulbar muscular atrophy. Neurology 2013, 80:2095-2098.
10. Hashizume A., Katsuno M., Banno H., et al. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain 2012, 135:2838-2848.
11. Guillemin F., Bombardier C., Beaton D. Cross-cultural adaptation of health related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1933, 46:1417-1432.
12. The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 1996, 53:141-147. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group.
13. Ohashi Y., Tashiro K., Itoyama Y., et al. Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS(ALSFRS-R) Japanese version. No to Shinkei 2001, 53:346-355.
14. Oda E., Ohashi Y., Tashiro K., et al. Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis. No to Shinkei 1996, 48:999-1007.
15. Nunnally J.C., Bemstein I.H. Psychometric theory 1994, McGraw-Hill, New York. 3rd ed.
16. Kazis L.E., Anderson J.J., Meenan R.F. Effect sizes for interpreting changes in health status. Med Care 1989, 27(3 Suppl.):S178-89.
17. Giordano A., Pucci E., Naldi P., et al. Responsiveness of patient reported outcome measures in multiple sclerosis relapses: the REMS study. J Neurol Neurosurg Psychiatry 2009, 80:1023-1028.
18. Schmitz-Hübsch T., Fimmers R., Rakowicz M., et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 2010, 74:678-684.
19. Burns J., Ouvrier R., Estilow T., et al. Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability. Ann Neurol 2012, 71:642-652.
20. Simmons Z., Felgoise S.H., Bremer B.A., et al. The ALSSQOL. Balancing physical and nonphysical factors in assessing quality of life in ALS. Neurology 2006, 67:1659-1664.
21. Shy M.E., Blake J., Krajewski K., et al. Reliability and validation of the CMT neuropathy score as a measure of disability. Neurology 2005, 64:1209-1214.
22. Müller J., Wissel J., Kemmler G., et al. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry 2004, 75:749-753.
23. Payan C.A., Viallet F., Landwehrmeyer B.G., et al. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS-Parkinson Plus Scale. PLoS ONE 2011, 6(8):e22293.
24. Hashizume A., Katsuno M., Banno H., et al. Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy. J Neurol 2012, 259:712-719.
25. Unified Huntington's disease rating scale: reliability and-consistency. Mov Disord 1996, 11:136-142. Huntington Study Group.
26. Wenning G.K., Tison F., Seppi K., et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004, 19:1391-1402.
27. Hobart J.C., Cano S.J., Zajicek J.P., et al. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 2007, 6:1094-1105.
28. Simon N.G., Lomen-Hoerth C., Kiernan M.C. Patterns of clinical and electrodiagnostic abnormality in early amyotrophic sclerosis. Muscle Nerve 2014, 50:894-899.
29. Ravits J.M., La Spada A.R. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 2009, 73:805-811.
30. Cicchetti F., Lacroix S., Cisbani G., et al. Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol 2014, 76:31-42.
31. Marder K., Zhao H., Myers R.H., et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 2000, 54:452-458.
32. Martinez-Martin P., Prieto L., Forjaz M.J. Longitudinal metric properties of disability rating scales for Parkinson's disease. Value Health 2006, 9:386-393.
33. Martínez-Martin P., Carod-Artal F.J., da Silveira Ribeiro L., et al. Longitudinal psychometric attributes, responsiveness, and importance of change: an approach using the SCOPA-Psychosocial questionnaire. Mov Disord 2008, 23:1516-1523.
34. Merkies I.S., Faber C.G. Outcome measures in Duchenne muscular dystrophy: are we ready for the new therapeutic era?. Neuromuscul Disord 2009, 19:447.
35. Draak T.H., Vanhoutte E.K., van Nes S.I., et al. Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology 2014, 83:2124-2132.
36. Vanhoutte E.K., Faber C.G., van Nes S.I., et al. Modifying the Medical Research Council grading system through Rasch analyses. Brain 2012, 135:1639-1649.
37. Smith A.G., Burns T.M. Reevaluating clinical measurement tools in therapeutic trials: time to make a Rasch decision?. Neurology 2014, 83:2104-2105.